Levocetirizine Pretreatment Mitigates Lipopolysaccharide-Induced Lung Inflammation in Rats

Alaa N. A. Fahmi, George S. G. Shehatou, and Hatem A. Salem

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Correspondence should be addressed to George S. G. Shehatou; georgeshehatou@gmail.com

Received 27 March 2018; Revised 27 July 2018; Accepted 31 July 2018; Published 13 August 2018

1. Introduction

Acute lung injury (ALI) is a critical pathological event that causes acute pulmonary failure and death. On the clinical ground, the term ALI has been widely replaced with the acute respiratory distress syndrome (ARDS), which is currently defined based on several diagnostic criteria [1]. The mortality of patients suffering from ARDS remains high, around 30-50%, despite substantial advances in intensive care [2]. The ALI/ARDS may arise due to a diverse set of inciting insults such as major trauma, burns, pneumonia, aspersion, and sepsis [1]. Of these factors, sepsis related to bacterial infection garners special interest since it remains the most common etiology of postsurgery and posttrauma deaths [3].

Lipopolysaccharide (LPS) is a component of the cell wall of gram negative bacteria. Its release is the main etiological factor of bacterial endotoxemia and sepsis, which are associated with sequential dysfunction of multiple organs, including lung, heart, liver, and kidney [4–6]. LPS is robustly used to elicit experimental ALI, which exhibits major features of lung tissue injury in human ARDS, including leukocyte infiltration, lung edema, abnormal gas exchange, and mortality [7, 8]. Potential contributing mechanisms include disruption of alveolar-capillary membrane integrity and excessive neutrophil infiltration into alveolar spaces [9]. Lung inflammation also triggers the generation of various inflammation-associated cytokines and reactive oxygen species (ROS) [7, 10]. Moreover, apoptosis takes place in several cell types that are located in the inflammatory lung milieu [7].

Histamine H₁-receptor antagonists represent a well-established therapeutic strategy for treatment of allergic and inflammatory diseases [11, 12]. The inflammation-inhibiting effects of H₁-receptor blockers have been linked to both H₁-receptor-dependent [13–15] and independent [15–17] mechanisms. This study was aimed to elucidate the influences of levocetirizine, a non-sedating H₁-antihistamine, on LPS-induced lung tissue damage and inflammation in rats.
2. Materials and Methods

2.1. Animals. Male Sprague Dawley rats (190-230 g) were supplied with standard diet and water ad libitum. The experimental protocols in this study conformed to the institutional and international guidelines for the ethical use of laboratory animals in research.

2.2. Materials. LPS was obtained from Sigma Chemical Co. (E. coli serotype O111:B4, St. Louis, MO, USA). It was dissolved in sterile saline on the day of experiment. Levocetirizine (Levcet tablets, Marcryl co., Cairo, Egypt) was administered as a suspension in 0.5% carboxymethyl cellulose (CMC).

2.3. Experimental Protocol. Rats were assigned into 2 groups (n = 6 each) at random, as follows: LPS received 0.5% CMC (2 ml/kg/day for a week, orally) and Levocetirizine + LPS administered with levocetirizine (1 mg/kg/day for a week, orally). On day 8, both groups received LPS (7.5 mg/kg, IP) to induce ALI, as previously described [18, 19]. Control group (n = 6) received 0.5% CMC (2 ml/kg/day for a week, orally) and was injected with sterile saline (0.9%, IP) on day 8.

The selected dose of levocetirizine was previously reported in rat studies [16, 20]. At this dose, levocetirizine only elicits peripheral H1 blockade due to poor penetration into the CNS [21].

18 h after LPS challenge, blood was collected and serum was separated for measurement of C-reactive protein (CRP). The chest was surgically opened at the midline and the bronchoalveolar lavage fluid (BALF) was collected as previously described [18]. Moreover, lungs were removed, washed, and used for assessment of lung water content and histopathological examination.

In another series of experiments, the left lungs of treated rats were removed, homogenized (1:10 w/v) in 50 mM phosphate buffer (pH 7.4), and centrifuged (5000 rpm, 4°C, 20 min). Supernatants were then collected for assessment of oxidative status and tumor necrosis factor-α (TNF-α).

2.4. BALF Biochemical Parameters. Commercial assay kits for determination of total protein concentration (Biodiagnostic, Giza, Egypt), lactate dehydrogenase (LDH) activity (Biosystems, Barcelona, Spain), and total nitrite and nitrate (NOx) levels (R and D Systems, Minneapolis, USA) were used.

2.5. Lung Wet/Dry (W/D) Weight Ratio. The lower right lung lobe was weighed after isolation (wet weight) and after drying at 80°C for 24 h (dry weight). The W/D ratio was determined.

2.6. Lung Oxidative Stress. Levels of reduced glutathione (GSH), malondialdehyde (MDA), and superoxide dismutase (SOD) activity in lung homogenates were assayed using commercial kits (Biodiagnostic, Giza, Egypt), following manufacturer's instructions and based on previously reported methods [22–24].

2.7. TNF-α Levels. TNF-α concentrations in lung homogenates and BALF were determined using an ELISA kit (eBioscience, San Diego, CA), following manufacturer's instructions.

2.8. Histopathological Assessments. The upper right lung lobe was fixed in buffered formalin and stained with hematoxylin and eosin (H&E). Histological changes indicative of ALI were assessed, including alveolar congestion, hemorrhage, neutrophil infiltration, alveolar wall thickness, and interstitial edema. Tissues were graded on a scale of 0-3 for each characteristic to obtain a total lung injury score, as previously described [18]. Histological evaluation was carried out by a pathologist who was unaware of group assignment.

2.9. Statistical Analysis. Results are shown as mean ± SEM. Statistical comparisons were made using one-way analysis of variance (ANOVA) followed by Tukey–Kramer post hoc test. Kruskal-Wallis followed by Dunn's test was used to compare histological lung scores in the study groups. The level of significance was set at P < 0.05. Graphpad Prism software (V6.03, CA, USA) was used for statistical data analysis.

3. Results

3.1. Serum CRP Level (Figure 1). Serum CRP levels were significantly higher in LPS-treated rats than control group (P < 0.0001), indicating an acute inflammation. Pretreatment of rats with levocetirizine restored normal serum level of CRP (P < 0.0001 compared to LPS group).

3.2. Lung W/D Weight Ratio (Figure 2). The lung W/D weight ratio was significantly elevated in LPS group (P < 0.001) compared with control rats. Levocetirizine pretreatment attenuated LPS-induced elevation in the lung W/D ratio (P < 0.05 relative to LPS-challenged rats).

3.3. BALF Protein Content and Total Cell Count. BALF protein content (Figure 3(a)) and total cell count (Figure 3(b)) were significantly increased in rats after LPS administration, effects that were markedly attenuated by prior treatment with levocetirizine.
versus LPS-treated and control groups, respectively. ∗ (P < 0.05) activity (P < 0.05, Figure 4(a)) and total NOx (P < 0.0001, Figure 4(b)) compared to control group. Levocetirizine restored normal BALF level of LDH (P > 0.05 relative to control group) and attenuated the increased concentrations of NOx in LPS group (P < 0.01 vs. both LPS and control groups).

3.5. Lung Oxidative Status (Figure 5). In LPS group, lung tissues exhibited significantly higher MDA levels (P < 0.01 vs. control) and significantly lower GSH (P < 0.0001 vs. control) and SOD activity (P < 0.001 vs. control). Levocetirizine administration abolished LPS-induced changes in MDA and SOD levels. However, lung GSH levels in LPS group were not altered by levocetirizine treatment.

3.6. Lung and BALF TNF-α Levels. LPS-treated rats demonstrated significant increases of the levels of the proinflammatory TNF-α in the BALF (P < 0.0001) and lung homogenates (P < 0.001) relative to control group. LPS-mediated elevations of BALF and lung TNF-α level were significantly improved by prior treatment with levocetirizine (Figure 6).

3.7. Lung Histology. Control rats demonstrated normal pulmonary histology (Figure 7(a)). Examination of lung tissues of LPS-administered animals (Figure 7(b)) revealed substantial histopathological changes, including interstitial and alveolar edema, hemorrhage, alveolar wall thickening, and neutrophil infiltration into the interstitial and alveolar spaces when compared to the control group. These histological alterations were markedly ameliorated in the levocetirizine-pretreated rats (Figure 7(c)). A semiquantitative analysis of the histological changes in lung tissues in all groups is shown in Figure 8. The total lung injury scores in LPS-treated rats (9-14; median = 11) were significantly higher (P < 0.01) when compared with normal rats (0-2; median = 0). The lung injury scores in LPS + levocetirizine group (2-4; median = 3) were less than those in LPS-administered rats, indicating a protective effect of levocetirizine pretreatment against LPS-induced histopathological alterations.

4. Discussion

An intraperitoneal LPS challenge was used to provoke lung inflammation and injury in rats in the current study. Intratracheal [7], intravenous [19], and intraperitoneal [18] administrations of LPS to rats have been reported to elicit experimental ALI that closely resembles human ALI/ARDS. In the present study, LPS-challenged rats exhibited major features of ALI, including (i) a significant elevation of lung W/D ratio (indicating tissue edema), (ii) a marked increase in BALF total cells (indicating infiltration of activated inflammatory cells into lung tissue), (iii) an increased BALF level of total protein content (indicating enhanced alveolar-capillary membrane permeability of the barrier), and (iv) characteristic histopathological alterations in lung tissues. The findings of the current study suggest that levocetirizine pretreatment may mitigate ALI via suppression of oxidative damage and inflammation.

LPS administration elicited a marked oxidative stress in lung tissues, which showed an increase of lipid peroxidation and marked reductions in SOD activity and GSH levels. Oxidative injury is a key player in the development of ALI [7, 10]. Recruitment and activation of inflammatory cells during lung injury result in the overproduction of ROS, which interact with various cellular macromolecules and ultimately lead to disruption of lung function parameters [25, 26]. Natural host defenses fail to restore oxidant/antioxidant balance despite ALI-induced activation of antioxidant enzyme systems [27].

In the present study, levocetirizine offered antioxidant influences in LPS-challenged rats. Lung lipid peroxidation was reduced and SOD activity was substantially elevated in rats that were pretreated with levocetirizine compared with the untreated LPS group. Supporting these findings, levocetirizine ameliorated high fructose diet-induced hepatic oxidative stress in rats [16]. Paradoxically, levocetirizine failed to restore normal lung GSH concentrations.

Possible mechanisms that may mediate the antioxidative effects of levocetirizine include H1 receptor blockade. Histamine was shown to stimulate release of hydrogen peroxide by primary bronchial epithelial cells via H1 receptor-dependent signaling [28]. Several H1-antihistamines diminished the production of ROS in neutrophils isolated from rat blood [29]. Moreover, it may be possible that levocetirizine inactivates ROS through direct scavenging activity or via activation of SOD, the only antioxidant enzyme that can scavenge superoxide [30]. Interestingly, it has also been shown that levocetirizine enhanced production of thioredoxin, a natural ROS scavenger, in hydrogen peroxide-stimulated macrophages [31]. Furthermore, levocetirizine may attenuate oxidant generation by reducing alveolar infiltration of inflammatory cells. Cetirizine inhibited recruitment and activation of inflammatory cells and suppressed production of reactive oxygen radicals, lipid mediators, and proinflammatory cytokines at sites of inflammation [32–35].
The beneficial influences of levocetirizine may be mediated via attenuation of LPS-induced increase of BALF NO level. The elevation of pulmonary NO was reported to contribute to ALI-associated inflammation, oxidative stress, and cytotoxicity [36, 37]. NO reacts with superoxide anion, generating peroxynitrite anion, which decomposes into highly reactive oxidative radicals [38]. Moreover, peroxynitrite modifies protein structure by reacting with various amino acids such as cysteine and tyrosine. These reactions impair cell signal transduction [39], resulting in apoptosis and dysfunction of microvascular endothelial barrier [40, 41]. Overproduction of lung NO in LPS-treated rats may be related to an enhanced expression of the inducible NO synthase (iNOS) [37, 42]. It remains to be investigated whether levocetirizine influences pulmonary iNOS expression in LPS-challenged rats. H₁ receptor antagonists have been shown to inhibit NO production by LPS-stimulated murine macrophages via downregulation of iNOS protein expression [43]. Interestingly, the degree of inhibition of nitrite accumulation by H₁ antihistamines correlated well with their degree of lipophilicity [43], which may explain failure of levocetirizine, a low lipophilicity H₁ antihistamine [44, 45], to completely abolish LPS-mediated increase of pulmonary NO in the current investigation.

Lung inflammation occurs in response to injurious insults, which include bacterial endotoxemia and exposure to toxic chemicals [10, 18, 46]. The inflammatory response involves activation of several types of inflammatory cells, which release proinflammatory cytokines, such as TNF-α and interleukin (IL)-6. Secreted cytokines contribute to progression of inflammation via enhancement of expression of adhesion molecules on microvascular endothelium and stimulation of chemotaxis and activation of neutrophils, which release ROS, proteolytic enzymes, and additional cytokines [46–48].

In the current study, levocetirizine pretreatment attenuated LPS-induced inflammation. Rats preadministered with levocetirizine showed significant decreases in serum CRP,
Figure 5: Effects of levocetirizine on lung oxidative stress in LPS-challenged rats. (a) malondialdehyde (MDA), (b) glutathione (GSH) and (c) superoxide dismutase (SOD). Results are shown as means ± SEM of 6 rats in each group. * and # are significantly different (P < 0.05) versus LPS-treated and control groups, respectively.

Figure 6: Effects of levocetirizine on tumor necrosis factor-α (TNF-α) levels in bronchoalveolar lavage fluid (BALF, panel (a)) and lung tissue (panel (b)) of LPS-challenged rats. Results are shown as means ± SEM of 6 rats in each group. * and # are significantly different (P < 0.05) versus LPS-treated and control groups, respectively.

Levocetirizine attenuated LPS-induced increase of TNF-α level in BALF and lung tissue. This is consistent with other studies [8, 49]. TNF-α contributes to LPS-induced ALI via different mechanisms. TNF-α promotes the infiltration of neutrophils into lung [50]. Moreover, TNF-α increases ROS generation by neutrophils [51]. Therefore, the protective effect
of levocetirizine against LPS-induced ALI is possibly mediated via suppression of the proinflammatory TNF-α in the lung tissue. The anti-inflammatory potential of levocetirizine may also be dependent on its ability to mitigate oxidative stress in the lung milieu since excessive production of ROS can trigger the expression of proinflammatory cytokines [7, 51].

LPS administration also resulted in cytotoxicity, as indicated by increased BALF levels of the cytosolic enzyme, LDH. Levocetirizine pretreatment attenuated the elevation of LDH level, implying a cytoprotective effect. Histopathological assessments of the lung tissues further emphasized the protective effects of levocetirizine against LPS-induced tissue damage.

The molecular mechanisms involved in the antioxidant and anti-inflammatory activities exerted by levocetirizine were not addressed in the present study. Histamine concentrations have been shown to increase in BALF of rats with LPS-induced ALI [52], possibly via LPS induction of the histamine-forming enzyme histidine decarboxylase in the lung tissues [53, 54]. Histamine is reported to play contradictory roles in immune cell-driven inflammation depending on the histamine receptor subtype involved and consequently the distinct downstream regulatory pathways activated. It has been demonstrated that histamine increases the release of proinflammatory IL-6 by lung macrophages via H1 receptor.
activation [55], whereas it inhibits chemotaxis, phagocytosis, and production of TNF-α and superoxide anion via H$_1$ receptors [56, 57]. Therefore, a possible explanation of the findings in the present study is that blockade of pulmonary H$_1$ receptors by levocetirizine reduces LPS-induced lung inflammation, allowing histamine to exert unopposed anti-inflammatory roles via H$_2$ receptors, which have been reported to mediate protective effects in LPS-induced tissue injury [58]. This speculation needs to be investigated in future research.

In the current study, levocetirizine was administered at a dose of 1 mg/kg/day, which corresponds to, based on dose conversion between rat and human [59], the recommended therapeutic dose in human, 10 mg/day. Moreover, administration of levocetirizine (1 mg/kg) in rats resulted in only 22.5% occupancy of the brain H$_1$ receptors, indicating that levocetirizine, at this dose level, exerts effective peripheral H$_1$ blockade without central adverse effects [21, 60]. Furthermore, levocetirizine (1 mg/kg) treatment exhibited anti-inflammatory and antioxidative effects in rats [16, 61, 62].

In conclusion, the present study suggests that levocetirizine, a non-sedating H$_1$-receptor antagonist, ameliorates lung injury-associated vascular permeability, edema, and histopathological changes in LPS-challenged rats.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] E. Fan, D. Brodie, and A. S. Slutsky, "Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment," JAMA, vol. 319, pp. 698–710, 2018.

[2] J. Maca, O. Jor, M. Holub et al., “Past and Present ARDS Mortality Rates: A Systematic Review,” Respiratory Care, vol. 62, pp. 113–122, 2017.

[3] W. Y. Kim and S. B. Hong, "Sepsis and Acute Respiratory Distress Syndrome: Recent Update," in Tuberc Respir Dis (Seoul), vol. 79, pp. 53–57, 2016.

[4] Y. Y. Jung, Y. Nam, Y. S. Park et al., "Protective effect of phosphatidylcholine on lipopolysaccharide-induced acute inflammation in multiple organ injury," The Korean Journal of Physiology & Pharmacology, vol. 17, pp. 209–216, 2013.

[5] A. E. Khodir, H. A. Ghoneim, M. A. Rahim, and G. M. Suddek, "Montelukast reduces sepsis-induced lung and renal injury in rats," Canadian Journal of Physiology and Pharmacology, vol. 92, pp. 839–847, 2014.

[6] M. A. Dkhil, R. B. Kassab, S. Al-Quraishy, M. M. Abdel-Daim, R. Zrieq, and A. E. Abdel Moneim, "Ziziphus spina-christi (L.) leaf extract alleviates myocardial and renal dysfunction associated with sepsis in mice," Biomedicine & Pharmacotherapy, vol. 102, pp. 64–75, 2018.

[7] C. Fu, X. Dai, Y. Yang, M. Lin, Y. Cai, and S. Cai, "Dexametomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats," Molecular Medicine Reports, vol. 15, pp. 131–138, 2017.

[8] X. Hu, Y. Tian, S. Qu et al., “Protective effect of TM6 on LPS-induced acute lung injury in mice,” Scientific Reports, vol. 7, p. 572, 2017.

[9] K. Baudiss, R. de Paula Vieira, S. Cicko et al., “CIP Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-kappaB Activation in Neutrophils,” The Journal of Immunology, vol. 196, pp. 2339–2326, 2016.

[10] Z. Dong and Y. Yuan, “Accelerated inflammation and oxidative stress induced by LPS in acute lung injury: Iotanhibition by ST1926,” International Journal of Molecular Medicine, vol. 41, pp. 3405–3421, 2018.

[11] F. E. Simons and K. J. Simons, “Histamine and H1-antihistamines: celebrating a century of progress,” Journal of Allergy and Clinical Immunology, vol. 128, pp. 1139–1150, 2011.

[12] G. Liu, X. Zhou, J. Chen, and F. Liu, "Oral Antihistamines Alone vs in Combination with Leukotriene Receptor Antagonists for Allergic Rhinitis: A Meta-analysis," in Otolaryngology–Head and Neck Surgery, vol. 158, pp. 450–458, 2018.

[13] R. A. Bakker, S. B. Schoonruis, M. J. Smilt, H. Timmerman, and R. Leurs, "Histamine H1-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling," Molecular Pharmacology, vol. 60, pp. 1133–1142, 2001.

[14] M. Triggiani, A. Petraroli, S. Loffredo et al., “Differentiation of monocytes into macrophages induces the upregulation of histamine H1 receptor,” The Journal of Allergy and Clinical Immunology, vol. 119, no. 2, pp. 472–481, 2007.

[15] C. Roumanest, C. Henrique, C. Gougat et al., "Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and - independent mechanisms," Clinical & Experimental Allergy, vol. 38, no. 6, pp. 947–956, 2008.

[16] N. M. Shawky, G. S. G. Shehatou, M. Abdel Rahim, G. M. Suddek, and N. M. Gameil, "Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats," European Journal of Pharmacology, vol. 740, pp. 353–363, 2014.

[17] H. S. Anbar, G. S. G. Shehatou, G. M. Suddek, and N. M. Gameil, "Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats," European Journal of Pharmacology, vol. 780, pp. 82–92, 2016.

[18] A. N. A. Fahmi, G. S. G. Shehatou, A. M. Shebl, and H. A. Salem, "Fexofenadate protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner," Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 389, no. 3, pp. 269–278, 2016.

[19] P. Li, Y. M. Yang, and S. Sanchez, “Deubiquitinase MYSMI is essential for normal bone formation and mesenchymal stem cell differentiation,” Scientific Reports, vol. 6, Article ID 22211, 2016.

[20] J. K. Ryu and S. D. Yoo, "Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextro- cetirizine," Journal of Pharmacy & Pharmaceutical Sciences, vol. 15, no. 4, pp. 519–527, 2012.

[21] A. Gupta, M. Gillard, B. Christophe, P. Chatelain, R. Massingham, and M. Hammarlund-Udenaes, “Peripheral and central H 1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig,”
R. F. Guo and P. A. Ward, "Role of oxidants in lung injury during sepsis," *British Journal of Pharmacology*, vol. 151, no. 7, pp. 1129–1136, 2007.

E. Beutler, O. Durno, and B. M. Kelly, "Improved method for the determination of blood glutathione," *Journal of Laboratory and Clinical Medicine*, vol. 61, pp. 882–888, 1963.

M. Nishikimi, N. Appaji Rao, and K. Yagi, "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen," *Biochemical and Biophysical Research Communications*, vol. 46, no. 2, pp. 849–854, 1972.

K. Satoh, "Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method," *Clinica Chimica Acta*, vol. 90, no. 1, pp. 37–43, 1978.

J. Bhattacharyya, S. Biswas, and A. G. Datta, "Mode of action of endotoxin: role of free radicals and antioxidants," *Current Medicinal Chemistry*, vol. 11, pp. 359–368, 2004.

R. A. Kozar, C. J. Weibel, J. Cipolla et al., "Antioxidant enzymes and their role in sepsis," *Antioxidants & Redox Signaling*, vol. 9, no. 11, pp. 1991–2002, 2007.

R. A. Kozar, C. J. Weibel, J. Cipolla et al., "Antioxidant enzymes are induced during recovery from acute lung injury," *Critical Care Medicine*, vol. 28, no. 7, pp. 2486–2491, 2000.

B. Rada, H. E. Boudreau, J. J. Park, and T. L. Leto, "Histamine stimulates hydrogen peroxide production by bronchial epithelial cells via histamine H1 receptor and dual oxidase," *American Journal of Respiratory Cell and Molecular Biology*, vol. 50, no. 1, pp. 125–134, 2014.

A. Lojeek, M. Ciz, M. Pekarova et al., "Modulation of metabolic activity of phagocytes by antihistamines," *Interdiscip Toxicol*, vol. 4, pp. 15–19, 2011.

V. L. Kinnula and J. D. Crapo, "Superoxide dismutases in the lung and human lung diseases," *American Journal of Respiratory and Critical Care Medicine*, vol. 167, pp. 1600–1619, 2003.

T. Mizuyoshi, M. Asano, A. Furuta, K. Asano, and H. Kobayashi, "Influence of Histamine H1 Receptor Antagonists on Thioredoxin Production In vitro and In vivo," *Journal of Allergy and Therapy*, vol. 8, pp. 258–264, 2017.

E. N. Charlesworth, A. Kagey-Sobotka, P. S. Norman, and L. M. Lichtenstein, "Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late-phase reaction," *The Journal of Allergy and Clinical Immunology*, vol. 83, no. 5, pp. 905–912, 1989.

T. Jinquan, C. M. Reimert, B. Deleuran, C. Zachariae, C. Simonsen, and K. Thesstrup-Pedersen, "Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes," *The Journal of Allergy and Clinical Immunology*, vol. 95, no. 5, pp. 979–986, 1995.

R. Arnold, J. Rihoux, and W. Konig, "Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549)," *Clinical & Experimental Allergy*, vol. 29, pp. 1681–1691, 1999.

T. Shimizu, J. Nishihira, H. Watanabe, R. Abe, T. Ishibashi, and H. Shimizu, "Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action," *Clinical & Experimental Allergy*, vol. 34, no. 1, pp. 103–109, 2004.

S. Mehta, "The effects of nitric oxide in acute lung injury," *Vascular Pharmacology*, vol. 43, no. 6, pp. 390–403, 2005.

H. X. Zhang, S. J. Liu, X. L. Tang et al., "H2S Attenuates LPS-Induced Acute Lung Injury by Reducing Oxidative/Nitritative Stress and Inflammation," *Cellular Physiology and Biochemistry*, vol. 40, pp. 1603–1612, 2016.

S. Rehberg, M. O. Maybauer, D. M. Maybauer, L. D. Traber, P. Enkhbaatar, and D. L. Traber, "The role of nitric oxide and reactive nitrogen species in experimental ARDS," *Frontiers in Bioscience - Scholar*, vol. 2, no. 1, pp. 18–29, 2010.

P. Pacher, J. S. Beckman, and L. Laird, "Nitric oxide and peroxynitrite in health and disease," *Physiological Reviews*, vol. 87, no. 1, pp. 315–424, 2007.

Z. Gu, Y. Ling, and B. Cong, "Peroxynitrite mediated acute lung injury induced by lipopolysaccharides in rats," *Zhonghua Yi Xue Za Zhi*, vol. 80, no. 1, pp. 58–61, 2000.

C. Sittipunt, K. P. Steinberg, J. T. Ruzinski et al., "Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome," *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 2, pp. 503–510, 2001.

Z. Yu, J. P. Ouyang, and Y. P. Li, "Dexamethasone attenuated endotoxin-induced acute lung injury through inhibiting expression of inducible nitric oxide synthase," *Clinical Hemorheology and Microcirculation*, vol. 41, pp. 117–125, 2009.

J. Kralova, L. Rackova, M. Pekarova et al., "The effects of HI-antihistamines on the nitric oxide production by RAW 264.7 cells with respect to their lipophilicity," *International Immunopharmacology*, vol. 9, pp. 990–995, 2009.

A. Pagliara, B. Testa, P.-A. Carrupt et al., "Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist," *Journal of Medicinal Chemistry*, vol. 41, no. 6, pp. 853–863, 1998.

C. Chen, "Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine," *Current Medicinal Chemistry*, vol. 15, no. 21, pp. 2173–2191, 2008.

R. M. Labib, F. S. Youssef, M. L. Ashour, M. M. Abdel-Daim, and S. A. Ross, "Chemical composition of pinus roxburghii bark volatile oil and validation of its anti-inflammatory activity using molecular modelling and bleomycin-induced inflammation in Albino Mice," *Molecules*, vol. 22, no. 9, 2017.

B. Moldoveanu, P. Otomishi, P. Jani et al., "Inflammatory mechanisms in the lung," *Journal of Inflammation Research*, vol. 2, pp. 1–11, 2009.

I. T. Lee and C. M. Yang, "Inflammatory signalings involved in airway and pulmonary diseases," *Mediators of Inflammation*, Article ID 791231, 2013.

F. Tang, K. Pan, K. Wang, and C. Bian, "Atractylodin attenuates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome and TLR4 pathways," *Journal of Pharmacological Sciences*, vol. 136, pp. 203–211, 2018.

M. Shimizu, N. Hasegawa, T. Nishimura et al., "Effects of tnf-α converting enzyme inhibition on acute lung injury induced by endotoxin in the rat," *Shock*, vol. 32, no. 5, pp. 535–540, 2009.

M. Mittal, M. R. Siddiqui, K. Tran, S. P. Reddy, and A. B. Malik, "Reactive oxygen species in inflammation and tissue injury," *Antioxidants & Redox Signaling*, vol. 20, no. 7, pp. 1126–1147, 2014.

T.-H. Kim, H. J. Yoon, C. M. Lim, E.-K. Kim, M. J. Kim, and Y. Koh, "The role of endogenous histamine on the pathogenesis of the lipopolysaccharide (LPS)-induced, acute lung injury: A pilot study," *Inflammation*, vol. 29, no. 2-3, pp. 8–16, 2005.

X. Wu, A. Yoshida, T. Sasanou, Y. Iwakura, and Y. Endo, "Histamine production via mast cell-independent induction of histidine decarboxylase in response to lipopolysaccharide and interleukin-1," *International Immunopharmacology*, vol. 4, no. 4, pp. 513–520, 2004.
[54] C. Smuda, J. B. Wechsler, and P. J. Bryce, “TLR-induced activation of neutrophils promotes histamine production via a PI3 kinase dependent mechanism,” *Immunology Letters*, vol. 141, no. 1, pp. 102–108, 2011.

[55] G. Marone, M. Gentile, A. Petraroli, N. De Rosa, and M. Triggiani, “Histamine-induced activation of human lung macrophages,” *International Archives of Allergy and Immunology*, vol. 124, pp. 249–252, 2001.

[56] E. Vannier, L. C. Miller, and C. A. Dinarello, “Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors,” *Journal of Experimental Medicine*, vol. 174, pp. 281–284, 1991.

[57] Y. Azuma, M. Shinohara, P.-L. Wang, A. Hidaka, and K. Ohura, “Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFα and IL-12 by macrophages via H2-receptors,” *International Immunopharmacology*, vol. 1, no. 9-10, pp. 1867–1875, 2001.

[58] T. Masaki, S. Chiba, H. Tatsukawa et al., “The role of histamine H1 receptor and H2 receptor in LPS-induced liver injury,” *The FASEB Journal*, vol. 19, no. 10, pp. 1245–1252, 2005.

[59] A. B. Nair and S. Jacob, “A simple practice guide for dose conversion between animals and human,” *Journal of Basic and Clinical Pharmacy*, vol. 7, pp. 27–31, 2016.

[60] A. M. Snowman and S. H. Snyder, “Cetirizine: Actions on neurotransmitter receptors,” *The Journal of Allergy and Clinical Immunology*, vol. 86, no. 6, pp. 1025–1028, 1990.

[61] A. Deiteren, J. G. De Man, N. E. Ruysers, T. G. Moreels, P. A. Pelckmans, and B. Y. De Winter, “Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity,” *Gut*, vol. 63, no. 12, pp. 1873–1882, 2014.

[62] A. Deiteren, L. Van Der Linden, A. De Wit et al., “P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization,” *PLoS ONE*, vol. 10, no. 4, Article ID e0123810, 2015.